Neurogene Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Neurogene Inc. (NGNE) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $8.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-11
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $8.00K.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $15.00K.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $22.00K.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $33.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $8.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $15.00K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $22.00K 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $33.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $45.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $58.00K 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $71.00K 10-K · filed 2026-03-24 | |
| 2024-09-30 | $84.00K 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $96.00K 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $87.00K 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $98.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $87.00K 10-K · filed 2024-03-18 | $500.00K 10-K · filed 2023-03-20 |
| 2022-09-30 | $200.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $200.00K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $200.00K 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $200.00K 10-K · filed 2023-03-20 | |
| 2021-09-30 | $200.00K 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $300.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $300.00K 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $300.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $200.00K 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $300.00K 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $300.00K 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $300.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |